Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Wohl

Showing results (111-120 of 185) with videos related to

Pageof 19
Sort By:
Antiviral Therapy|August 30, 2013
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) studyDavid A Wohl, Gretchen Arnoczy, Carl J Fichtenbaum, et al.
Health Security|August 21, 2024
Building Clinical Care Capacity for Patients With Special Pathogens in Advance of the Next OutbreakLauren Wiesner, Jade Flinn, Brooke Brewer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 11, 2013
Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009Hao Zhu, Sonia Napravnik, Joseph J Eron, et al.
The Journal of Infectious Diseases|May 10, 2002
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267David A Wohl, Francesca T Aweeka, John Schmitz, et al.
The Lancet. HIV|May 10, 2019
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialDavid A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 22, 2013
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 resultsDavid A Wohl, Calvin Cohen, Joel E Gallant, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2012
Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) studyDavid A Wohl, Julie B Dumond, Suzanne Blevins, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
Scientific Reports|March 20, 2026
Association of long COVID with health-related quality-of-life outcomesMalini M Gandhi, Carlee Moser, Judith S Currier, et al.
Annals of Internal Medicine|February 21, 2023
Symptom and Viral Rebound in Untreated SARS-CoV-2 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Pageof 19

Showing results (111-120 of 185) with videos related to

Sort By:
Pageof 19
Antiviral Therapy|August 30, 2013
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) studyDavid A Wohl, Gretchen Arnoczy, Carl J Fichtenbaum, et al.
Health Security|August 21, 2024
Building Clinical Care Capacity for Patients With Special Pathogens in Advance of the Next OutbreakLauren Wiesner, Jade Flinn, Brooke Brewer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 11, 2013
Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009Hao Zhu, Sonia Napravnik, Joseph J Eron, et al.
The Journal of Infectious Diseases|May 10, 2002
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267David A Wohl, Francesca T Aweeka, John Schmitz, et al.
The Lancet. HIV|May 10, 2019
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialDavid A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 22, 2013
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 resultsDavid A Wohl, Calvin Cohen, Joel E Gallant, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2012
Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) studyDavid A Wohl, Julie B Dumond, Suzanne Blevins, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
Scientific Reports|March 20, 2026
Association of long COVID with health-related quality-of-life outcomesMalini M Gandhi, Carlee Moser, Judith S Currier, et al.
Annals of Internal Medicine|February 21, 2023
Symptom and Viral Rebound in Untreated SARS-CoV-2 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
Pageof 19